Early Phase 1 N=11 Testing an Adjustable Ankle Orthosis During Walking in Cerebral Palsy
Cerebral Palsy
Primary: Change in Muscle Activity — -0.09 percent change based on mV/mV measures
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
Phase 3 N=503 A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Percent Change From Baseline in PASI at Week 12 — 85.7; 86.3 Percent change
Phase 2 N=34 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Raynaud Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -14.32; -15.09 Number of RP attacks per week — p=0.8498
N/A N=44 Variability and Specificity in Reactive Stabilization Movements to Diverse Slip Perturbations
Slip Perturbations
Primary: Fall Rates — 18.3; 16.0 Percentage of trials resulting in falls.
Phase 1 N=38 Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Myelodysplastic Syndrome · Myelofibrosis · Chronic Myeloid Leukemia
Primary: Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t) — 1065; 1024 ng*hr/mL
Phase 3 N=196 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -11.47; -12.73 Number of RP attacks per week — p=0.4210
N/A N=70 Effect of Irrigation-Activation Techniques on Healing in Large Periapical Lesions
Effect of Irrigation Activation on Periapical Healing
Primary: Percentage Change in Lesion Volume at 12-months Follow-up — 80.429; 85.429; 86.929; 74.571 percent change — p=<0.05
Phase 2 N=24 Eyelid Androgen Treatment in Dry Eye
Aqueous Tear Deficiency · Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Primary: Tear Break up Time — 0.0; 2.9 seconds
N/A N=230 Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy
Pseudophakia
Primary: Binocular DCNVA (Distance Corrected Near Visual Acuity) at 40cm — 0.03; 0.01 logMAR
Phase 2 N=52 Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Adverse Events Occurring Over the Trial Period — 37; 5; 6; 12 Participants
Phase 3 N=10 Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use
Opioid Use
Primary: Morphine Milligram Equivalents Used During Inpatient Stay — 10.8; 8.8 morhpine milligram equivalents
N/A N=200 Hybrid Coronary Revascularization Trial
Coronary Artery Disease
Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year
N/A N=42 Clinical Evaluation of MucoPEG™ for Xerostomia
Dry Mouth · Xerostomia
Primary: Change in VAS for Mouth Dryness — -0.8; -0.7; -1.5; -0.4 score on a scale — p=<0.01
N/A N=58 The Loneliness Epidemic Tailoring Interventions to Reduce Loneliness and Pain
Pain, Chronic · Loneliness
Primary: Self-reported Pain Severity — 2.57; 3.71; 3.22; 3.89 score on a scale — p=.05